The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - ARIAD; AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - ARIAD; AstraZeneca; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Roche
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Ignyta; KSQ Therapeutics; Loxo; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Solange Peters
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Jin Seok Ahn
Honoraria - AstraZeneca; Janssen; Lilly; Menarini; Roche
Consulting or Advisory Role - Boehringer Ingelheim
 
Sai-Hong Ignatius Ou
No Relationships to Disclose
 
Maurice Perol
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Rafal Dziadziuszko
Honoraria - Boehringer Ingelheim; Clovis Oncology; Novartis; Pfizer; Roche; Tesaro
Consulting or Advisory Role - Boehringer Ingelheim; Ignyta
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Roche
 
Dong-Wan Kim
No Relationships to Disclose
 
Rafael Rosell
No Relationships to Disclose
 
Ali Hassan Zeaiter
Employment - Proacta
Leadership - Proacta
Stock and Other Ownership Interests - Proacta
 
Ting Liu
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Sophie Golding
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Bogdana Balas
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Johannes Noé
Employment - Roche
 
Peter N. Morcos
Employment - Roche
Stock and Other Ownership Interests - Roche
 
D. Ross Camidge
Research Funding - Roche (Inst)